Condition
Klippel Trenaunay Syndrome
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06789913Phase 2Recruiting
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT05563831Completed
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
NCT01364857Not ApplicableCompleted
French National Cohort of Children With Port Wine Stain
NCT03001180Recruiting
Identification of Biomarkers for Patients with Vascular Anomalies
NCT04836884Not ApplicableCompleted
Vascular Anomaly Pathology and Genomics Biopsy Study
Showing all 5 trials